Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By

26 Results

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 11/23/2020

    Contains 5 Component(s), Includes Credits Includes a Live Web Event on 11/23/2020 at 8:00 PM (EST)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 11/14/2020

    Contains 5 Component(s), Includes Credits Includes a Live Web Event on 11/14/2020 at 8:00 AM (EST)

    This is PART 1 of the waiver eligibility training. A total of 8-hours of training is required for physicians and a total of 24 hours is required for NPs and PAs. Please see overview for additional details. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    As of the requirements to obtain the waiver, physicians without specified experience must complete not less than 8 hours of training. A total of 8 hours of training is federally mandated for physicians and a total of 24 hours of training is mandated for NPs and PAs.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session as part of the process to obtain a waiver for prescribing buprenorphine.

    Instructions on how to log on to the second half of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please note that in order to be eligible for the waiver to prescribe Buprenorphine, you must complete a total of 8 hours consisting of the live webcast session (4.25-hours) and the online self-study session and exam (3.75-hours) within 30 days of the live webcast session. The AOAAM cannot verify completion of the webinar session if less than 4.25 hours are attended. Should you not attend for the entire session, you will have to retake the entire webinar again on a different date in order to get credit. Please be aware that it is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions in order for the AOAAM to verify your attendance. The combined live webcast and online self-study training will provide 8 hours to be applied toward obtaining the waiver to prescribe buprenorphine in office-based treatment of opioid dependence. Physicians who complete this course will meet the training qualification under the new law. For NPs and PAs, an additional 16-hours of training will be required for waiver eligibility.

     

    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • Q&A Session: Telehealth to Improve Access to Mental Health and Substance Use Disorder Treatment for Pregnant and Postpartum Women

    Contains 3 Component(s) Includes a Live Web Event on 11/11/2020 at 6:00 PM (EST)

    This is the sixth Q & A webinar in the telehealth series for the Opioid Response Network (ORN). Post your questions at: https://docs.google.com/document/d/1jWnx8vzasVmq_zIV9nLWIRr4qYJ14oiYHYr7w2HTd1w/edit?usp=sharing Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This is the sixth Q & A webinar in the telehealth series for the Opioid Response Network (ORN).

    Q&A Session for the 11/11/2020 webinar. Post your questions at: https://docs.google.com/docume...

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Constance Guille, MD

    Dr. Constance Guille is a Professor in the Department of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology at the Medical University of South Carolina (MUSC) and director of the Women’s Reproductive Behavioral Health Division at MUSC. This division provides mental health and substance use disorder treatment to pregnant and postpartum women and conducts clinical research that aims to improve the identification and treatment of peripartum mental health and substance use disorders. Dr. Guille receives research support through National Institute on Drug Abuse and foundations such as the Duke Endowment to develop treatments that leverage technology to improve maternal health.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Telehealth to Improve Access to Mental Health and Substance Use Disorder Treatment for Pregnant and Postpartum Women

    Contains 3 Component(s) Includes a Live Web Event on 11/04/2020 at 6:00 PM (EST)

    This is the sixth webinar in the telehealth series for the Opioid Response Network (ORN). The webinar will describe the use of telemedicine to create integrated mental health and substance use disorder treatment services for pregnant and postpartum women receiving prenatal care in an obstetric setting. The webinar will describe outcomes for pregnant women with Opioid Use Disorder and how technology is being leveraged during COVID-19 to improve detection and treatment of maternal mental health and substance use disorders. Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This is the sixth webinar in the telehealth series for the Opioid Response Network (ORN).

    The webinar will describe the use of telemedicine to create integrated mental health and substance use disorder treatment services for pregnant and postpartum women receiving prenatal care in an obstetric setting. The webinar will describe outcomes for pregnant women with Opioid Use Disorder and how technology is being leveraged during COVID-19 to improve detection and treatment of maternal mental health and substance use disorders.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Constance Guille, MD

    Dr. Constance Guille is a Professor in the Department of Psychiatry and Behavioral Sciences and Obstetrics and Gynecology at the Medical University of South Carolina (MUSC) and director of the Women’s Reproductive Behavioral Health Division at MUSC. This division provides mental health and substance use disorder treatment to pregnant and postpartum women and conducts clinical research that aims to improve the identification and treatment of peripartum mental health and substance use disorders. Dr. Guille receives research support through National Institute on Drug Abuse and foundations such as the Duke Endowment to develop treatments that leverage technology to improve maternal health.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Q&A Session: The Current Evidence On Telemedicine-Delivered Treatment for Opioid and Other Substance Use Disorders

    Contains 3 Component(s) Recorded On: 10/21/2020

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN). Post your questions at: https://docs.google.com/document/d/1LdLKYrpNQuJFbGzZYo6kTXYiXN_hSh_lByDdBBmtwiY/edit?usp=sharing Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN).

    Q&A Session for the 10/14/2020 webinar. Post your questions at: https://docs.google.com/docume...

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Allison Lin, MD

    Allison Lin, MD is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry as well as a research investigator at the VA Center for Clinical Management Research. She investigates ways to improve treatment for patients with opioid and other substance use disorders and uses large electronic health datasets to better understand medical, mental health and other correlates for patients with substance use disorders. Dr. Lin is interested in developing telehealth interventions to improve access to evidence based treatments for substance use disorders and to better understand disparities in treatment. 

    Areas of Interest

    ·         Improving access to opioid and other substance use disorder treatment

    ·         Improving care for patients with substance and other comorbid mental health disorders

    ·         Reducing drug overdose

    ·         Interventions to promote safer opioid prescribing

    Credentials

    ·         Addiction Psychiatry Research & Clinical Fellow, Department of Psychiatry, University of Michigan Medical School 

    ·         Adult Psychiatry Residency, Department of Psychiatry, University of Michigan Medical School

    ·         M.D. Yale University School of Medicine B.S. in Chemical Engineering and Economics, Massachusetts Institute of Technology

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • The Current Evidence On Telemedicine-Delivered Treatment for Opioid and Other Substance Use Disorders

    Contains 3 Component(s)

    This is the fifth webinar in the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This is the second part of the fifth webinar in the telehealth series for the Opioid Response Network (ORN).

    This presentation will describe background on current challenges with substance use disorder (SUD) treatment access and delivery and present evidence for telemedicine for SUD treatment based on a recent systematic review published by the speaker and describe gaps in the research knowledge to date. 

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Allison Lin, MD

    Allison Lin, MD is an addiction psychiatrist and Assistant Professor in the Department of Psychiatry as well as a research investigator at the VA Center for Clinical Management Research. She investigates ways to improve treatment for patients with opioid and other substance use disorders and uses large electronic health datasets to better understand medical, mental health and other correlates for patients with substance use disorders. Dr. Lin is interested in developing telehealth interventions to improve access to evidence based treatments for substance use disorders and to better understand disparities in treatment. 

    Areas of Interest

    ·         Improving access to opioid and other substance use disorder treatment

    ·         Improving care for patients with substance and other comorbid mental health disorders

    ·         Reducing drug overdose

    ·         Interventions to promote safer opioid prescribing

    Credentials

    ·         Addiction Psychiatry Research & Clinical Fellow, Department of Psychiatry, University of Michigan Medical School 

    ·         Adult Psychiatry Residency, Department of Psychiatry, University of Michigan Medical School

    ·         M.D. Yale University School of Medicine B.S. in Chemical Engineering and Economics, Massachusetts Institute of Technology

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Q&A - Telemedicine for OUD in the Indian Health Service

    Contains 3 Component(s) Recorded On: 08/26/2020

    This webinar is part of the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This webinar is part of the telehealth series for the Opioid Response Network (ORN).

    Please submit your questions for this session using this link: https://docs.google.com/docume...

    Patients who receive care in the IHS system often live in rural areas where economic and transportation challenges can make accessing medications for OUD treatment difficult.  Telemedicine can remove many barriers to OUD treatment for Native American/Alaskan patients.  Dr. Spencer will discuss how telemedicine for OUD is being used in the Alaskan native medical system and elsewhere.  Topics covered will include IHS specific legal concerns,  home induction and remote urine drug testing, remote harm reduction services, remote behavioral health support and use of monthly injectable medications.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Sarah Spencer, DO

    Dr. Spencer grew up rural central Maine and did her medical training there during the peak of the Oxycontin epidemic in 2001-2009.  She is board certified in family and addiction medicine has been providing treatment for OUD in rural Alaska since 2010.   For the past 5 years Dr. Spencer has been providing opioid overdose response training and naloxone distribution, and 2016 she became the medical director and founding member of Alaska’s only rural syringe access program.  She is currently an employee of the Ninilchik Traditional Council and provides family medicine and addiction treatment services at their tribal clinic, including telemedicine to remote native villages.  She teaches on addiction issues across the state of Alaska, including buprenorphine waiver certification courses. She participated in the treatment advisory committee for developing the 2019 Alaska state opioid task force recommendations and co-authoring the state’s medication assisted treatment guide and is the state’s senior physician consultant for the SAHMSA funded Opioid Response Network consulting program.  

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Telemedicine for OUD in the Indian Health Service

    Contains 3 Component(s)

    This is the fourth webinar in the telehealth series for the Opioid Response Network (ORN). Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or oganizations imply endorsement by the U.S. Government.

    This is the fourth webinar in the telehealth series for the Opioid Response Network (ORN).

    Patients who receive care in the IHS system often live in rural areas where economic and transportation challenges can make accessing medications for OUD treatment difficult.  Telemedicine can remove many barriers to OUD treatment for Native American/Alaskan patients.  Dr. Spencer will discuss how telemedicine for OUD is being used in the Alaskan native medical system and elsewhere.  Topics covered will include IHS specific legal concerns,  home induction and remote urine drug testing, remote harm reduction services, remote behavioral health support and use of monthly injectable medications.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Sarah Spencer, DO

    Dr. Spencer grew up rural central Maine and did her medical training there during the peak of the Oxycontin epidemic in 2001-2009.  She is board certified in family and addiction medicine has been providing treatment for OUD in rural Alaska since 2010.   For the past 5 years Dr. Spencer has been providing opioid overdose response training and naloxone distribution, and 2016 she became the medical director and founding member of Alaska’s only rural syringe access program.  She is currently an employee of the Ninilchik Traditional Council and provides family medicine and addiction treatment services at their tribal clinic, including telemedicine to remote native villages.  She teaches on addiction issues across the state of Alaska, including buprenorphine waiver certification courses. She participated in the treatment advisory committee for developing the 2019 Alaska state opioid task force recommendations and co-authoring the state’s medication assisted treatment guide and is the state’s senior physician consultant for the SAHMSA funded Opioid Response Network consulting program.  

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Q&A Session - Telehealth for Opioid Use Disorder during the COVID-19 Pandemic and Beyond

    Contains 3 Component(s)

    This is the Q&A session for the third webinar in the telehealth series for the Opioid Response Network (ORN). There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders. This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted. Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This is the Q&A session for the third webinar in the telehealth series for the Opioid Response Network (ORN).

    There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders.   

     This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Shabana Khan, MD

    Shabana Khan, MD has a decade of experience in telemedicine. She is an Assistant Professor and the Director of Telepsychiatry for the Department of Child and Adolescent Psychiatry at NYU Langone Health in New York City.

    She is Co-Chair of the American Academy of Child and Adolescent Psychiatry (AACAP) Telepsychiatry Committee, Chair of the NYU Grossman School of Medicine Telemedicine Taskforce, and member of the American Psychiatric Association (APA) Telepsychiatry Committee.

    Dr. Khan is an expert in undergraduate and graduate medical education and training in telemedicine.

    Through her active involvement and collaboration with the American Telemedicine Association (ATA), APA, AACAP, and Center for Telehealth and e-Health Law (CTeL), Dr. Khan has helped inform telemedicine legislation, policy, and regulations at the federal and state level.

    Dr. Khan received a B.A. in Neuroscience from Barnard College and an M.D. from SUNY Downstate College of Medicine. She completed general adult psychiatry residency and child and adolescent psychiatry fellowship at Western Psychiatric Hospital of the University of Pittsburgh Medical Center (UPMC). She is board-certified in General Psychiatry and Child and Adolescent Psychiatry.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

  • Telehealth for Opioid Use Disorder during the COVID-19 Pandemic and Beyond

    Contains 3 Component(s)

    This is the third webinar in the telehealth series for the Opioid Response Network (ORN). There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders. This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted. Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    This is the third webinar in the telehealth series for the Opioid Response Network (ORN).

    There have been significant telehealth legal, regulatory, and reimbursement changes at the federal and state level in the context of the COVID-19 pandemic. These changes have allowed for a rapid expansion of telehealth nationally, including for the assessment and treatment of mental health and substance use disorders.   

     This webinar, hosted by the American Osteopathic Academy of Addiction Medicine through a Opioid Response Network STR-TA grant, will cover the telehealth legal, regulatory, clinical, and reimbursement landscape prior to and during the pandemic. The webinar will focus on telehealth for the treatment of opioid use disorder and will include an overview of key laws and regulations including the Ryan Haight Act, the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, and relevant changes made during the national public health emergency (PHE). The webinar will include a discussion of what the future telehealth landscape may look like once the national PHE and state-by-state executive orders and emergency declarations are lifted.

    Funding for this initiative was made possible (in part) by grant no. 6H79TI080816 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Shabana Khan, MD

    Shabana Khan, MD has a decade of experience in telemedicine. She is an Assistant Professor and the Director of Telepsychiatry for the Department of Child and Adolescent Psychiatry at NYU Langone Health in New York City.

    She is Co-Chair of the American Academy of Child and Adolescent Psychiatry (AACAP) Telepsychiatry Committee, Chair of the NYU Grossman School of Medicine Telemedicine Taskforce, and member of the American Psychiatric Association (APA) Telepsychiatry Committee.

    Dr. Khan is an expert in undergraduate and graduate medical education and training in telemedicine.

    Through her active involvement and collaboration with the American Telemedicine Association (ATA), APA, AACAP, and Center for Telehealth and e-Health Law (CTeL), Dr. Khan has helped inform telemedicine legislation, policy, and regulations at the federal and state level.

    Dr. Khan received a B.A. in Neuroscience from Barnard College and an M.D. from SUNY Downstate College of Medicine. She completed general adult psychiatry residency and child and adolescent psychiatry fellowship at Western Psychiatric Hospital of the University of Pittsburgh Medical Center (UPMC). She is board-certified in General Psychiatry and Child and Adolescent Psychiatry.

    Julie Kmiec, DO, FAOAAM (Moderator)

    AOAAM President

    Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.